Canadian Journal of Gastroenterology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Canadian Association of Gastroenterology Awards Presented at Canadian Digestive Diseases Week 2015.
29:130-130.
2015
-
Canadian Association of Gastroenterology Position Statement: Hip Fracture and Proton Pump Inhibitor Therapy – a 2013 Update.
27:593-595.
2013
-
Closure of a Percutaneous Endoscopic Gastrostomy-Associated Nonhealing Gastrocutaneous Fistula Using Endoscopic Hemoclips.
27:501-502.
2013
-
General Anesthetic Versus Light Sedation: Effect on Pediatric Endoscopy Wait Times.
27:519-522.
2013
-
Patient-Identified Quality Indicators for Colonoscopy Services.
27:25-32.
2013
-
Summary of Guidelines for Infection Prevention and Control for Flexible Gastrointestinal Endoscopy.
27:347-350.
2013
-
The 2012 Sage Wait Times Program: Survey of Access to Gastroenterology in Canada.
27:83-89.
2013
-
The Burden of Celiac Disease in Canada: More Work Needed to Lighten the Load.
27:448-448.
2013
-
A Canadian Working Group Report on Fecal Microbial Therapy: Microbial Ecosystems Therapeutics.
26:457-462.
2012
-
A Survey of the Practice of After-Hours and Emergency Endoscopy in Canada.
26:871-876.
2012
-
An Audit of Influenza Vaccination Status in Adults with Inflammatory Bowel Disease.
26:593-596.
2012
-
Canadian Association of Gastroenterology Consensus Guidelines on Safety and Quality Indicators in Endoscopy.
26:17-31.
2012
-
Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement.
26:819-829.
2012
-
Helicobacter pyloriin First Nations and Recent Immigrant Populations in Canada.
26:97-103.
2012
-
Implementation of a Multidisciplinary Team Approach and Fish Oil Emulsion Administration in the Management of Infants with Short Bowel Syndrome and Parenteral Nutrition-Associated Liver Disease.
26:277-280.
2012
-
Indicators of Safety Compromise in Gastrointestinal Endoscopy.
26:71-78.
2012
-
Report on the Expert Forum on using Information Technology to Facilitate Uptake and Impact of Colorectal Cancer Screening Guidelines.
26:902-904.
2012
-
Safety of Esophagogastroduodenoscopy within 30 Days of Myocardial Infarction: A Retrospective Cohort Study from a Canadian Tertiary Centre.
26:151-154.
2012
-
Serious Events in Older Ontario Residents Receiving Bowel Preparations for Outpatient Colonoscopy with Various Comorbidity Profiles: A Descriptive, Population-Based Study.
26:436-440.
2012
-
A Literature Review of Quality in Lower Gastrointestinal Endoscopy from the Patient Perspective.
25:681-685.
2011
-
A Survey of Sedation Practices for Colonoscopy in Canada.
25:255-260.
2011
-
Epidemiology and Burden of Chronic Constipation.
25:11B-15B.
2011
-
Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada).
25:503-510.
2011
-
Point-of-Care, Peer-Comparator Colonoscopy Practice Audit: The Canadian Association of Gastroenterology Quality Program – Endoscopy.
25:13-20.
2011
-
Should Albumin Be Used in All Patients with Spontaneous Bacterial Peritonitis?.
25:373-376.
2011
-
Testing for Gluten-Related Disorders in Clinical Practice: The Role of Serology in Managing the Spectrum of Gluten Sensitivity.
25:193-197.
2011
-
A One-Year Economic Evaluation of Six Alternative Strategies for the Management of Uninvestigated Upper Gastrointestinal Symptoms in Canadian Primary Care.
24:489-498.
2010
-
Ranking in Canadian Gastroenterology Residency Match: What Do Residents and Program Directors Want?.
24:369-372.
2010
-
Should My Patient with Inflammatory Bowel Disease on Immunosuppressive Therapy be Vaccinated against Influenza Virus?.
24:121-125.
2010
-
Summary of the Canadian Association of Gastroenterology 2004 Strategic Plan.
24:164-167.
2010
-
Survey of Access to GastroEnterology in Canada: The SAGE Wait Times Program.
24:20-25.
2010
-
The Safety of Infliximab Infusions in the Community Setting.
24:307-311.
2010
-
Adherence to Guidelines for Surveillance Colonoscopy in Patients with Ulcerative Colitis at a Canadian Quaternary Care Hospital.
23:613-617.
2009
-
Assessing the Educational Needs of Canadian Gastroenterologists and Gastroenterology Nurses: Challenges to Optimal Care in Crohn’s Disease.
23:805-810.
2009
-
Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?.
23:121-125.
2009
-
Myocardial Infarction, Peptic Ulcer and Acetylsalicylic Acid: Of Good and Evil.
23:618-618.
2009
-
Prevention ofClostridium difficileInfection withSaccharomyces boulardii: A Systematic Review.
23:817-821.
2009
-
Proton Pump Inhibitors and Clopidogrel – Hazardous Drug Interaction or Hazardous Interpretation of Data?.
23:251-252.
2009
-
Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy.
23:180-184.
2009
-
Training General Surgery Residents on the Gastroenterology Service: A Look at the Successes and Challenges.
23:342-344.
2009
-
Access to Specialist Gastroenterology Care in Canada: Comparison of Wait Times and Consensus Targets.
22:161-167.
2008
-
Access to Specialist Gastroenterology Care in Canada: The Practice Audit in Gastroenterology (PAGE) Wait Times Program.
22:155-160.
2008
-
Canadian Credentialing Guidelines for Colonoscopy.
22:17-22.
2008
-
Canadian Credentialing Guidelines for Endoscopic Retrograde Cholangiopancreatography.
22:547-551.
2008
-
Canadian Credentialing Guidelines for Esophagogastroduodenoscopy.
22:349-354.
2008
-
Canadian Credentialing Guidelines for Flexible Sigmoidoscopy.
22:115-119.
2008
-
Exercise and Inflammatory Bowel Disease.
22:497-504.
2008
-
Hip Fracture and Proton Pump Inhibitor Therapy: Position Statement.
22:855-856.
2008
-
La Fracture de la Hanche et la Thérapie par Inhibiteurs de la Pompe à Protons : Un Document de Principes.
22:857-858.
2008
-
Low Prevalence ofHelicobacter PyloriInfection in Canadian Children: A Cross-Sectional Analysis.
22:485-489.
2008
-
Propofol Use for Sedation during Endoscopy in Adults: A Canadian Association of Gastroenterology Position Statement.
22:457-459.
2008
-
Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis.
22:261-272.
2008
-
The Irritable Infection.
22:669-670.
2008
-
The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada.
22:388-392.
2008
-
Canadian Credentialing Guidelines for Endoscopic Privileges: An Overview.
21:797-801.
2007
-
Cancer Care Ontario Colonoscopy Standards: Standards and Evidentiary Base.
21:5D-24D.
2007
-
Clinical Onset of Celiac Disease after an Episode ofCampylobacter jejuniEnteritis.
21:453-455.
2007
-
Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients.
21:637-642.
2007
-
Low Risk of Irritable Bowel Syndrome afterClostridium difficileInfection.
21:727-731.
2007
-
Maintenance Treatment of Gastroesophageal Reflux Disease: An Evaluation of Continuous and On-Demand Therapy with Rabeprazole 20 mg.
21:820-826.
2007
-
Photodynamic Therapy for Barrett’s Esophagus with High-Grade Dysplasia: A Cost-Effectiveness Analysis.
21:217-222.
2007
-
Recommendations on Chronic Constipation (including Constipation Associated with Irritable Bowel Syndrome) Treatment.
21:3B-22B.
2007
-
The Effect of Sham Feeding on Neurocardiac Regulation in Healthy Human Volunteers.
21:721-726.
2007
-
The Promises and Perils of Nurse-Led Flexible Sigmoidoscopy Screening.
21:280-282.
2007
-
Who Provides Gastrointestinal Endoscopy in Canada?.
21:843-846.
2007
-
C-13 urea breath test for Helicobacter pylori: Determination of the optimal cut-off point in a Canadian community population.
20:770-774.
2006
-
C-13 urea breath test for Helicobacter pylori: Evaluation of 10-minute breath collection.
20:775-778.
2006
-
13C Urea Breath Test for Helicobacter pylori: Determination of the Optimal Cut-Off Point in a Canadian Community Population.
20:770-774.
2006
-
13C Urea Breath Test forHelicobacter pylori: Evaluation of 10-minute Breath Collection.
20:775-778.
2006
-
Commonly Used Preparations for Colonoscopy: Efficacy, Tolerability and Safety – A Canadian Association of Gastroenterology Position Paper.
20:699-710.
2006
-
Finding Inflammatory Bowel Disease Genes Will Not Lead to a Cure.
20:643-644.
2006
-
Practice Audit in Gastroenterology (Page) Program: A Novel Approach to Continuing Professional Development.
20:405-410.
2006
-
Reporting Ileocolonoscopy in Inflammatory Bowel Disease.
20:399-400.
2006
-
Ambulatory Endoscopy – Perspectives from the Community.
19:471-473.
2005
-
An Update on Anti-Helicobacter Pylori Treatment in Children.
19:441-445.
2005
-
Anticoagulants and Gastrointestinal Bleeding.
19:535-537.
2005
-
Canadian Helicobacter Study Group Consensus Conference: Update on the Approach to Helicobacter Pylori Infection in Children and Adolescents – an Evidence-Based Evaluation.
19:399-408.
2005
-
Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool.
19:285-303.
2005
-
Should We Test for Helicobacter Pylori before Treating Gastroesophageal Reflux Disease?.
19:425-427.
2005
-
The Role of Gemcitabine in the Treatment of Cholangiocarcinoma and Gallbladder Cancer: A Systematic Review.
19:711-716.
2005
-
Validation of a Short Questionnaire in English and French for Use in Patients with Persistent Upper Gastrointestinal Symptoms Despite Proton Pump Inhibitor Therapy: The Pass (Proton Pump Inhibitor Acid Suppression Symptom) Test.
19:350-358.
2005
-
A Canadian Clinical Practice Algorithm for the Management of Patients with Non-Variceal Upper Gastrointestinal Bleeding.
18:605-609.
2004
-
Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease.
18:503-508.
2004
-
Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on Colon Cancer Screening.
18:93-99.
2004
-
Canadian Helicobacter Study Group Consensus Conference: Update on the Management ofHelicobacter pylori- An Evidence-Based Evaluation of Six Topics Relevant to Clinical Outcomes in Patients Evaluated forH pyloriInfection.
18:547-554.
2004
-
Helicobacter pylori and the Prevention of Gastric Cancer.
18:295-302.
2004
-
Injection of Botulinum Toxin a to Upper Esophageal Sphincter for Oropharyngeal Dysphagia in Two Patients with Inclusion Body Myositis.
18:397-399.
2004
-
Talk Is Cheap: The Impact of Consultation. Commentary on the Article.
18:181-182.
2004
-
cagA-Seropositive Strains ofHelicobacter pyloriIncrease the Risk for Gastric Cancer more than the Presence ofH pyloriAlone.
18:341-343.
2004
-
A Randomized Trial Comparing Seven-Day Ranitidine Bismuth Citrate and Clarithromycin Dual Therapy to Seven-Day Omeprazole, Clarithromycin and Amoxicillin Triple Therapy for the Eradication ofHelicobacter pylori.
17:533-538.
2003
-
Helicobacter pyloriTwenty Years on....
17:7B-7B.
2003
-
How Can the Current Strategies forHelicobacter pyloriEradication Therapy be Improved?.
17:36B-40B.
2003
-
Motion-Cyclo-oxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs are as Safe as Placebo for the Stomach: Arguments for the Motion.
17:339-341.
2003
-
Synchronous Epithelioid Stromal Tumour and Lipoma in the Stomach.
17:374-375.
2003
-
The Establishment of a National Tissue Bank for Inflammatory Bowel Disease Research in Canada.
17:107-109.
2003
-
The Evolving Epidemiology ofHelicobacter pyloriInfection and Gastric Cancer.
17:18B-20B.
2003
-
Validation of the GSFQ, a Self-Administered Symptom Frequency Questionnaire for Patients with Gastroesophageal Reflux Disease.
17:307-312.
2003
-
Re: Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol 2002; 16 : 231-40 - Response.
16:651-652.
2002
-
Early Relief of Upper Gastrointestinal Dyspeptic Symptoms: A Survey of Empirical Therapy with Pantoprazole in Canadian Clinical Practice.
16:439-450.
2002
-
Etiology of Dyspepsia: Implication for Empiric Therapy.
16:635-641.
2002
-
Motion – All Patients with GERD Should Be Offered Once in a Lifetime Endoscopy: Arguments for the Motion.
16:549-551.
2002
-
Motion – Screening and Surveillance of Barrett’s Epithelium Is Practical and Cost Effective: Arguments against the Motion.
16:541-545.
2002
-
Recommendations for the Appropriate Use of Anti-Inflammatory Drugs in the Era of the Coxibs: Defining the Role of Gastroprotective Agents.
16:231-240.
2002
-
Resource Utilization for Acute Lower Gastrointestinal Hemorrhage: The Ontario GI Bleed Study.
16:677-682.
2002
-
Risks and Benefits ofHelicobacter pyloriEradication: Current Status.
16:57-62.
2002
-
Self-Reported Awareness and Use ofInternational Classification of DiseaseCoding of Inflammatory Bowel Disease Services by Ontario Physicians.
16:519-526.
2002
-
Two Decades ofHelicobacter pylori: A Review of the Fourth Western PacificHelicobacterCongress.
16:559-563.
2002
-
Bismuth-Based Quadruple Therapy with Bismuth Subcitrate, Metronidazole, Tetracycline and Omeprazole in the Eradication ofHelicobacter pylori.
15:581-585.
2001
-
Gastric Acid Secretory Response inHelicobacter pylori-Positive Patients with Duodenal Ulcer Disease.
15:29-39.
2001
-
Laparoscopic versus Open Bowel Resection for Crohn's Disease.
15:237-242.
2001
-
Peripheral Mechanisms of Symptom Generation in Irritable Bowel Syndrome.
15:14B-16B.
2001
-
Plexiform Neurofibroma of the Submandibular Salivary Gland in a Child.
15:835-837.
2001
-
Ranitidine bismuth citrate: A review.
15:389-398.
2001
-
A Critical Approach to Clinical Practice Guidelines.
14:505-509.
2000
-
Effects of In Vitro Antibiotic Resistance on Treatment: Bismuth-Containing Regimens.
14:885-889.
2000
-
From Bench to Bedside to Bug: An Update of Clinically Relevant Advances in the Care of Persons withHelicobacter pyloriAssociated Diseases.
14:188-198.
2000
-
Health Information Provided by Retail Health Food Outlets.
14:767-771.
2000
-
Hepatitis in Disseminated Bacillus Calmette-Guérin Infection.
14:333-336.
2000
-
Implications of Antibiotic Resistance in the Management ofHelicobacter pyloriInfection: CanadianHelicobacterStudy Group.
14:862-868.
2000
-
Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon.
14:77B-81B.
2000
-
Meeting Review –Helicobacter pylori: Basic Mechanisms to Clinical Cure 2000.
14:856-861.
2000
-
Obscure Gastrointestinal Bleeding: An Approach to Management.
14:111-118.
2000
-
Omeprazole Once or Twice Daily with Clarithromycin and Metronidazole forHelicobacter pyloriEradicaiton in a Canadian Community Practice.
14:27-31.
2000
-
Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori..
14:27-31.
2000
-
Test-and-Treat Strategies forHelicobacter pyloriin Uninvestigated Dyspepsia: A Canadian Economic Anaylsis.
14:379-388.
2000
-
13C-Urea breath tests are the noninvasive method of choice for Helicobacter pylori detection..
13:681-683.
1999
-
C-13-Urea breath tests are the noninvasive method of choice for Helicobacter pylori detection.
13:681-683.
1999
-
Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group..
13:213-217.
1999
-
CanadianHelicobacter pyloriConsensus Conference Update: Infections in Adults.
13:213-217.
1999
-
CanadianHelicobacterStudy Group Consensus Conference on the Approach toHelicobacter PyloriInfection in Children and Adolescents.
13:553-559.
1999
-
Current Status of the Irritable Bowel Syndrome.
13:7A-7A.
1999
-
Management of Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Disease by Acid Suppression.
13:135-142.
1999
-
Phlegmonous Gastritis Following Coronary Bypass Surgery.
13:837-839.
1999
-
Primary Biliary Cirrhosis and Type II Autoimmune Polyglandular Syndrome.
13:767-770.
1999
-
Role of Laparoscopic Antireflux Surgery in the Management of Chronic GERD Symptoms.
13:761-764.
1999
-
Stress, Inflammation and the Irritable Bowel Syndrome.
13:47A-49A.
1999
-
A Canadian Physician Survey of Dyspepsia Management.
12:83-90.
1998
-
Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology..
12:31-41.
1998
-
CanadianHelicobacter pyloriConsensus Conference.
12:31-41.
1998
-
From Bench to Bedside and Back – Report on the EuropeanHelicobacter pyloriStudy Group Xth International Workshop on Gastroduodenal Pathology andHelicobacter pylori.
12:437-446.
1998
-
Ketotifen Treatment of Active Colitis in Patients with 5-Aminosalicylate Intolerance.
12:273-275.
1998
-
Omeprazole for Refractory Gastroesophageal Reflux Disease during Pregnancy and Lactation.
12:225-227.
1998
-
Patients’ Diets and Preferences in a Pediatric Population with Inflammatory Bowel Disease.
12:544-549.
1998
-
The Evolving Role of Endoscopic Retrograde Cholangiography before and after Cholecystectomy.
12:187-191.
1998
-
The Second Canadian Gastroesophageal Reflux Disease Consensus: Moving Forward to New Concepts.
12:551-556.
1998
-
Helicobacter pylori: From bench to bedside (vol 11, pg 589, 1997).
11:646-646.
1997
-
Omeprazole--a new formulation..
11:655-656.
1997
-
Consensus Statement on Helicobacter pylori infection and its management..
11:548.
1997
-
Controversial issues in gastroesophageal reflux disease..
11 Suppl B:87B-90B.
1997
-
Efficacy of H2 receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms..
11 Suppl B:51B-54B.
1997
-
Health economics of gastroesophageal reflux disease..
11 Suppl B:108B-112B.
1997
-
Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview..
11 Suppl B:66B-73B.
1997
-
The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease..
11 Suppl B:7B-20B.
1997
-
Cost effectiveness of AlternativeHelicobacter pyloriEradication Strategies in the Management of Duodenal Ulcer.
11:323-331.
1997
-
Effect of Psychoneural Factors on Intestinal Epithelial Function.
11:353-357.
1997
-
Evaluation of Salivary Antibodies to Detect Infection with Helicobacter pylori.
11:437-440.
1997
-
Helicobacter pylori: From Bench to Bedside.
11:589-596.
1997
-
Successful Therapy of Refractory Erythema Nodosum Associated with Crohn's Disease Using Potassium Iodide.
11:501-502.
1997
-
Immunomodulation of Epithelium.
10:243-248.
1996
-
Role of Smooth Muscle in Intestinal Inflammation.
10:249-253.
1996
-
A Normal Appearing Duodenal Papilla in Familial Polyposis Need to be Biopsied: A Case Report.
9:75-77.
1995
-
The Gut-Brain Axis in IBD: An Investigator’s Perspective.
9:257-260.
1995
-
Granular Cell Tumour of the Bile Duct in Association with Intrahepatic Bile Duct Adenomas.
8:92-96.
1994
-
News from the Outgoing President.
8:293-294.
1994
-
Gatroesophagheal Reflux Therapy: What is the Role of Therapy?.
7:602-604.
1993
-
What Will Research Tell Us About the Future in IBD?.
7:51-54.
1993
-
Localization and Treatment of Small and Large Bowel Bleeding.
6:169-175.
1992
-
Canadian Consensus Conference on the Management of Gastroesophageal Reflux Disease in Adults – Update 2004
2005
-
Funding the New Biologics – CCOHTA Report on the Cost Effectiveness of Infliximab for Crohn’s Disease: Pearls and Pitfalls
2002
-
Hp and pH: Implications for the Eradication of Heliobacter pylori
1993
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)